Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Account Payables (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Change in Account Payables for 8 consecutive years, with -$461000.0 as the latest value for Q1 2026.

  • Quarterly Change in Account Payables rose 85.63% to -$461000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Feb 2026, down 27.71% year-over-year, with the annual reading at -$630000.0 for FY2025, 112.09% down from the prior year.
  • Change in Account Payables for Q1 2026 was -$461000.0 at Nurix Therapeutics, down from $3.0 million in the prior quarter.
  • The five-year high for Change in Account Payables was $7.6 million in Q4 2024, with the low at -$3.2 million in Q1 2025.
  • Average Change in Account Payables over 5 years is $342176.5, with a median of -$461000.0 recorded in 2026.
  • The sharpest move saw Change in Account Payables soared 617.24% in 2023, then crashed 332.5% in 2024.
  • Over 5 years, Change in Account Payables stood at -$899000.0 in 2022, then skyrocketed by 617.24% to $4.6 million in 2023, then soared by 63.12% to $7.6 million in 2024, then crashed by 60.12% to $3.0 million in 2025, then crashed by 115.24% to -$461000.0 in 2026.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$461000.0, $3.0 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.